Apremilast: target synthetic drug for the treatment of psoriatic arthritis and psoriasis
Apremilast (AP), a phosphodiesterase-4 inhibitor, is a novel drug for the treatment of psoriasis (Ps) and psoriatic arthritis (PsA). AP therapy affects the decrease in the activity of inflammatory changes due to reducing the level of proinflammatory cytokines. The clinical trials showed positive eff...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-07-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2577 |